Cytochrome P450 1B1 (CYP1B1), a member of CYP superfamily, is expressed in liver and extrahepatic tissues carries out the metabolism of numerous xenobiotics, including metabolic activation of polycyclic aromatic hydrocarbons. Surprisingly, CYP1B1 was also shown to be important in regulating endogenous metabolic pathways, including the metabolism of steroid hormones, fatty acids, melatonin, and vitamins. CYP1B1 and nuclear receptors including peroxisome proliferator-activated receptors (PPARs), estrogen receptor (ER), and retinoic acid receptors (RAR) contribute to the maintenance of the homeostasis of these endogenous compounds. Many natural flavonoids and synthetic stilbenes show inhibitory activity toward CYP1B1 expression and function, notably isorhamnetin and 2,4,3′,5′-tetramethoxystilbene. Accumulating evidence indicates that modulation of CYP1B1 can decrease adipogenesis and tumorigenesis, and prevent obesity, hypertension, atherosclerosis, and cancer. Therefore, it may be feasible to consider CYP1B1 as a therapeutic target for the treatment of metabolic diseases.
human CYP1B1 was cloned from primary cultures of normal human epidermal keratinocytes (Sutter et al., 1994) . In contrast to two other CYP1 family enzymes, CYP1A1 and CYP1A2, CYP1B1 is expressed in a variety of tumor tissues. Oral benzo [a] pyrene (B[a]P)-treated Cyp1a1/1a2/ 1b1(−/−) mice showed the same the "rescued" response as that seen in the Cyp1a1/1b1(−/−) mouse, whereas Cyp1a1(−/−) mice ingesting B[a]P died due to severe immunosuppression (Dragin et al., 2008) , suggesting that the CYP1B1 is necessary in immune tissues. In this study, it was also observed that the phenotype of oral B[a]P-treated Cyp1a1/1a2/ 1b1(−/−) mice was similar to that of the BaP-treated wild-type and the corn oil-treated control mice, whereas there was substantial bone marrow hypocellularity in oral B[a]P-treated Cyp1a1(−/−) and Cyp1a1/ 1a2(−/−) mice. These studies suggest that inhibition of CYP1B1 expression may contribute to the protection against bone marrow hypocellularity. An early study revealed that CYP1B1 was expressed in 122 of 127 tumor tissues, including brain, breast, and colon tumors (Murray et al., 1997) . The higher expression of CYP1B1 in tumor cells than the surrounding normal tissue has led to much interest on the role of CYP1B1 in tumorigenesis and its treatment.
The human CYP1B1 gene spanning 12 kb in length and located on chromosome region 2p21-22, consists of 3 exons and 2 introns (Tang et al., 1996) . Human CYP1B1 shows approximately 40% homology with CYP1A1 and CYP1A2, but its gene structure is simpler. The mRNA is 4.2 kb and its open reading frame begins at the second intron of 5′ end, coding a 543 amino acids residues protein (Murray, Melvin, Greenlee, & Burke, 2001) . Several positive and negative regulators exist in the promoter region of the human CYP1B1 gene, but it is structurally different from the genes encoding CYP1A1 and CYP1A2 Wo, Stewart, & Greenlee, 1997) . CYP1B1 is involved in the metabolism of a wide variety of xenobiotics, such as ethoxyresorufin, theophylline and caffeine, and shows some overlapping metabolic activities with CYP1A1 and CYP1A2. Unlike most CYPs, CYP1B1 expression is not detected in human liver, but CYP1B1 is expressed in many extrahepatic tissues, including lung, colon, eye and kidney. CYP1B1 shows activity toward activation of environmental carcinogens via the hydroxylation of procacinogens, including 27 polycyclic aromatic hydrocarbons and their derivatives, 17 heterocyclic and aryl amine and aminoazo dyes, 3 mycotoxins, 2 nitroaromatic hydrocarbons (Shimada et al., 1996) . Consistent with its role in carcinogen activation, carcinogenesis is reduced in Cyp1b1-null mice (Buters et al., 1999) , suggesting that CYP1B1 plays an important role in metabolic activation of environmental carcinogens.
The expression of CYP1B1 can be induced by xenobiotics such as TCDD, through the aryl hydrocarbon receptor (AHR) (Hankinson, 2016) . In addition to the oxidation of xenobiotics, CYP1B1 is involved in the metabolism of many important physiological compounds, including estrogen, arachidonic acid, melatonin and retinoids. A recent study revealed that Cyp1b1 disruption altered the expression of 560 liver genes, including suppression of peroxisome proliferator-activated receptor γ (PPARγ) and many genes regulated by PPARα (Larsen et al., 2015) . PPARs are a group of nuclear receptor that regulates the expression of many down-stream genes, and plays a key role in the homeostasis of lipids and glucose, closely related to metabolic diseases. Metabolic diseases are associated with the disorder of endogenous metabolism, ranging from obesity and atherosclerosis to hypertension and cancer. In terms of obesity, its incidence has been dramatically increased worldwide in recent years. It is estimated that N1/3 of adults and nearly 17% of children in the United States are obese. In 2008, the cost for obesity-related medical diseases was an estimated $147 billion. Some studies have shown that Cyp1b1 disruption can protect against obesity induced by high-fat diet (HFD) (Larsen et al., 2015; Li et al., 2014) . Previous reviews have discussed the role of CYP1B1 in glaucoma (Vasiliou & Gonzalez, 2008) . In this review, recent findings are summarized on the impact of CYP1B1 in the regulation of metabolic pathways and the development of metabolic diseases, and the potential therapy for the treatment of metabolic diseases using CYP1B1 modulators are discussed.
Discovery of CYP1B1 inhibitors
CYP1B1 is highly expressed in a wide of variety of cancers, such as prostate, uterus, and colon cancer. CYP1B1 is involved in the metabolic activation of many environmental procarcinogens. Mutant CYP1B1 alleles were detected in cancer and glaucoma patients. These findings suggest that the regulation of CYP1B1 expression could act as a therapeutic strategy, especially for cancer treatment. To date, N 50 natural products and synthetic compounds have been developed or identified as CYP1B1 inhibitors (Table 1) . Stilbene, flavonoids, coumarin, and anthraquinone are the four major types of compounds that inhibit CYP1B1 activity (Fig. 1) . 2,4,3′,5′-Tetramethoxystilbene (TMS), a methoxy derivative resveratrol, is a highly potent and selective inhibitor of CYP1B1. Its inhibitory ability for CYP1B1 (IC 50 = 6 nM) is over 50-fold greater than against CYP1A1 (IC 50 = 300 nM) and 500-fold higher than for CYP1A2 (IC 50 = 3000 nM) (Chun, Kim, et al., 2001) . It was reported that TMS can protect against chemically-induced and genetic hypertension. Natural flavonoids are an important source of CYP1B1 inhibitors. Methoxy types of flavones and flavonols were shown to selectively inhibit CYP1B1 activity, such as chrysoeriol and isorhamnetin. The synthetic α-naphthoflavone is a strong inhibitor of CYP1B1 (IC 50 = 5 nM) and CYP1A2 (IC 50 = 6 nM), compared to CYP1A1 (IC 50 = 60 nM) (Shimada et al., 1998) . More recently, a potent inhibitor of CYP1B1 (IC 50 = 0.043 nM) was synthesized from α-naphthoflavone, and its water-soluble derivative can eliminate the resistance of docetaxel in MCF-7/1B1 cells (Cui et al., 2015) . Several flavonoids from St. John's wort also show inhibitory activity on CYP1B1, including quercetin, rutin, apigenin, and amentoflavone (Chaudhary & Willett, 2006) . Some CYP1B1 inhibitors, such as kaempferol and isorhamnetin, can also antagonize the expression of AHR (Rajaraman, Yang, Chen, & Chang, 2009) , which lead to inhibition of the expression of CYP1B1. Thus, the inhibitory activity of CYP1B1 in mouse studies is difficult to interpret for both CYP1B1 inhibitors and AHR antagonists. Interestingly, some anticancer agents widely used in clinic are competitive inhibitors of CYP1B1, such as flutamide (IC 50 = 1.0 μM), paclitaxel (IC 50 = 31.6 μM), mitoxantrone (IC 50 = 11.6 μM), and docetaxel (IC 50 = 28.0 μM) (Rochat, Morsman, Murray, Figg, & McLeod, 2001 ). CYP1B1 inhibitors can be used to dissect CYP1B1 function and might be considered as therapeutic agents for the treatment of certain diseases as noted below.
Transgenic mouse models to determine the biological functions of CYP1B1
In 1999, a Cyp1b1 knockout mouse line was generated to determine the role of CYP1B1 in the metabolic activation of 7,12-dimethylbenz [a] anthracene (DMBA) (Buters et al., 1999) . It was noted that 70% of wild-type mice developed highly malignant lymphomas after administration with DMBA, whereas only 7.5% of Cyp1b1-null mice had lymphomas. Cyp1b1 disruption also reduced the tumorigenesis-induced by other procarcinogens, including benzo[a]pyrene (B[a]P) (Uno et al., 2006) and dibenzo [a,l] pyrene (DB[a,l]P) (Buters et al., 2002) . These studies demonstrated that CYP1B1 plays a key role in the metabolic activation of environmental procarcinogens. The role of CYP1B1 in primary congenital glaucoma (PCG) was also determined using Cyp1b1-null mice on a mixed 129 × 1/SvJ × C57BL/6 J background. The results showed that CYP1B1 deficiency damaged the ocular drainage structure and increased intraocular pressure (IOP), similar to the injury in human PCG patients (Libby et al., 2003) . Recently, Cyp1b1-null mice on a pure C57BL/6 J background were used to determine the effects of CYP1B1 on hypertension and obesity. To better understand the biological functions of CYP1B1, CYP1B1-humanized mice were created through the insertion of the complete native human CYP1B1 gene into the Cyp1b1-null mice genome. When fed with a high-fat diet (HFD), the weight gain in CYP1B1-humanized mice was similar to wild-type mice, which were higher than Cyp1b1-null mice (Li et al., 2014) . CYP1B1-humanized showed a similar response to the HFD as the wild-type mouse.
Therefore, transgenic CYP1B1 mice models are effective to define the biological effects of CYP1B1 on the development of metabolic diseases, endogenous metabolism and xenobiotic metabolism.
Metabolic pathways regulated by CYP1B1

Steroid hormone metabolism
Mouse models are effective to define the role of CYP1B1 in the development of metabolic diseases, endogenous metabolism and xenobiotic metabolism. Steroid hormones are the organic compound with four rings arranged in a specific configuration that can act as hormone. They can easily across cell membrane and bind to specific receptors forming hormone-receptor composite in cytoplasm. Steroid hormones are composed of five groups: glucocorticoid, mineralocorticoid, androgen, estrogen, and progestogen. Estrogen is the primary sex hormone in females, and is responsible for development and regulation of the female reproductive system. It is known that estrogen metabolism is associated with cancers and hypertension. Estrogen is converted to 17β-estradiol by 17β-hydroxylase. CYP1B1 carries out 4-hydroxylation of estradiol and exhibits the minor metabolic activity towards 2-hydroxylation ( Fig. 2) . The hydroxylated estradiol can be eliminated after further metabolism, such as methylation, glucuronidation or sulphonation; however, methylated metabolites of 4-OH-estradiol and 2-OH-estradiol also undergo demethylation by CYP1B1 (Dawling, Hachey, Roodi, & Parl, 2004) . 4-OH-Estradiol and 2-OH-estradiol are further transformed to semiquinones and quinones, which can form DNA adducts with resulting in oncogenic mutations (Embrechts et al., 2003; Markushin et al., 2003) . The quinones/ semiquinones also undergo redox cycling and generate reactive oxygen species (ROS), resulting in oxidative damage (Parl, Egan, Li, & Crooke, 2009) . Further examination revealed a role for CYP1B1 in estradiol carcinogenicity dependent on the amino acid in Val395 in the human CYP1B1 gene (Nishida, Everett, & Ortiz de Montellano, 2013) . Therefore, the carcinogenesis induced by estrogen metabolites attributed to CYP1B1, could be predicted by level of 4-OH-estradiol and its DNA adduct.
In addition, CYP1B1 is involved in the metabolism of testosterone and progesterone. Testosterone is a steroid hormone from the androgen group, which regulates the hypothalamic-pituitary-adrenal (HPA) axis (2008) response under activation of the thromboxane A2 receptor (Ajayi, Mathur, & Halushka, 1995; Mehta, Jones, & Josephs, 2008) . Metabolomics revealed a link between HPA axis and PPARα in controlling energy homeostasis and immune system (Wang et al., 2010) . Progesterone is a progestogen hormone involved in the production of other endogenous steroids, including sex hormones and corticosteroids, and plays an important role in the central nervous system. By comparison of the metabolism of testosterone, progesterone, and estradiol, the B-and D-ring metabolites are produced from testosterone and progesterone by CYP1B1 (Figs. 3 and 4), whereas the A-, B-and D-ring metabolites are transformed from estradiol (Jansson, Stoilov, Sarfarazi, & Schenkman, 2001 ). Compared to estrogen, testosterone and progesterone are poor substrate for CYP1B1. Approximately 70-80% metabolites from CYP1B1 metabolism are A-ring hydroxylation metabolites. Other minor metabolites are 6α/β-, 15α-and 16α-hydroxy products of estrogen, testosterone or progesterone. Androgen signaling can be reduced via the increased CYP1B1 expression in a mouse model (Hwang et al., 2003) . Thus, CYP1B1 might be relevant to androgen-mediated cancers.
Fatty acid metabolism
Fatty acids are a family of non-polar molecules classified as the lipid class. The role of fatty acids is energy production in the form of adenosine triphosphate (ATP) synthesis and energy storage in the free and conjugated form, including triacylglycerol and phospholipid. It is known that many diseases such as cancer and obesity are associated with fatty acid metabolism. Fatty acid metabolism is regulated by a set of nuclear receptors, including PPARα and PPARγ that play key roles in maintaining energy homeostasis. A recent study revealed that Cyp1b1 disruption suppressed the expression of the PPARγ and PPARα target genes, including differentiation 36 (CD36), CYP4A14 and acyl-CoA thioesterase 1 (ACOT1) (Larsen et al., 2015) . The body weight gain of Cyp1b1-null mice is significantly lower than wild-type mice when fed a HFD (Li et al., 2014) . Lipid synthesis including phospholipids and triglyceride was also decreased in Cyp1b1-null mice. These results indicate that CYP1B1 is an important modulator of fatty acids homeostasis.
Arachidonic acid (AA) is oxidized to prostaglandins, leukotrienes, and epoxyeicosatrienoic acids (EETs) by cyclooxygenase (COXs), lipoxygenase (LOs), and CYP (Capdevila & Falck, 2001; Roman, 2002) . Expoxygenases and hydroxylases are two major pathways of AA regulated by CYPs, which transform AA to EETs and hydroxyeicosatetraenoic acids (HETEs) (Fig. 5) , respectively (Roman, 2002) . The major metabolites of AA by human CYP1B1 are HETEs, including 20-HETE and 12-HETE (Choudhary, Jansson, Stoilov, Sarfarazi, & Schenkman, 2004) . The function of HETEs in cardiovascular has been summarized (Elbekai & El-Kadi, 2006; Roman, 2002) . Specifically, 20-HETEs takes part in anti-platelet activity (Hill, Fitzpatrick, & Murphy, 1992) , inhibition of renal Na + -K + -ATPase activity and sodium transport in proximal tubules (Schwartzman, Abraham, et al., 1985; Schwartzman, Ferreri, et al., 1985) , and regulation of the growth response in vascular smooth muscle cells (Muthalif et al., 1998) . 12-HETEs affects corneal susceptibility which has an influence on corneal clouding associated with glaucoma by regulating Na + -K + -ATPase activity (Masferrer, Dunn, & Schwartzman, 1990; Masferrer, Rios, & Schwartzman, 1990; Stiemke, Edelhauser, & Geroski, 1991) . One study showed that CYP1B1 preferentially produced midchain HETEs, whereas CYP1A1 showed a high specificity for ω-terminal region HETEs and CYP1A2 produced EETs (Choudhary et al., 2004) . In contrast to human CYP1B1, the major metabolites of arachidonic acid by mouse CYP1B1 were EETs. EETs were shown to have anti-inflammation (Node et al., 1999) , anti-apoptotic (Chen, Capdevila, & Harris, 2001) , vasodilating (Pomposiello, Carroll, Falck, & McGiff, 2001) , fibrinolytic (Node et al., 2001 ) and anti-fibrotic (Levick, Loch, Taylor, & Janicki, 2007) functions. The differences in AA metabolism between human CYP1B1 and mouse CYP2B1 might be due to differences in catalytic efficiency of mouse CYP1B1 that is significantly lower than the human ortholog.
Vitamin Metabolism
Vitamin is a family of organic compounds with diverse biochemical functions essential normal physiological functions. CYP1B1 is involved in the metabolism of vitamin A and shows a synergistic effect with other vitamins. Vitamin A is important for the growth and development, and maintains the immune system and good vision. The major forms of vitamin A include retinol, retinal and retinoic acid. Studies revealed that CYP1B1 was able to catalyze the oxidative metabolism of retinol to retinal and transform retinal into retinoic acid (Fig. 6) (Choudhary et al., 2004; Zhang, Dunbar, & Kaminsky, 2000) . Further studies indicated that the oxidation of retinol to retinoic acid was regulated by both human and mouse CYP1B1, but neither human or mouse CYP1B1 was found to oxidize retinoic acid. Compared to mouse CYP1B1, human CYP1B1 shows higher catalytic efficiency for the two step oxidation from retinol to retinoic acid (Choudhary et al., 2004) . Retinoic acid can trigger retinoid-mediated signaling pathways via binding to retinoic acid receptors (RAR) that has been considered as a therapeutic target in the treatment of dyslipidemia, atherosclerosis and cancer (Connolly, Nguyen, & Sukumar, 2013; Jakel, Fruchart-Najib, & Fruchart, 2006) . More recently, metabolomics analysis reveals that α-tocopherol, a biologically active form of vitamin E, can be oxidized to several metabolites via β-oxidation and ω-oxidation by CYPs, however, the specific CYPs carrying out these reactions were not identified in this study (Johnson et al., 2012) . Additionally, a clinical study indicated that genetic variations in CYP1B1 and serum 25-hydroxyvitamin D levels showed synergistic effect on blood pressure (Park et al., 2015) . These data suggest that CYP1B1 might be an important regulator for the diseases related to vitamin deficiency.
Melatonin Metabolism
Melatonin is a functionally diverse and ubiquitously distributed methoxyindole molecular with activity from unicellular organisms to animals. Melatonin is produced from tryptophan and serotonin in the pineal gland and then released to the blood by the control of sympathetic nerve, and the circulating melatonin can then be absorbed into liver. There are three main metabolic pathways for melatonin, hydroxylation, O-demethylation and deacetylation (Ma, Idle, Krausz, & Gonzalez, 2005) . 6-Hydroxylation of melatonin is catalyzed by hepatic CYPs, and its products are further sulfated and excreted in urine (Skene et al., 2001) . It was demonstrated using recombinant human CYPs that CYP1A1, CYP1A2, and CYP1B1 6-hydroxylate melatonin (Fig. 7) (Ma et al., 2005; Tijmes, Pedraza, & Valladares, 1996) . 6-Hydroxylation melatonin can be decreased in wild-type mouse brain homogenates by the CYP1B1 inhibitor TMS, and shows lower activity in Cyp1b1-null mouse brain homogenates compared to wild-type mice (Ma et al., 2005) . However, TMS treatment did not further reduce the 6-hydroxylation of melatonin in Cyp1b1-null mouse brain homogenates, suggesting a role for CYP1B1 in the generation of 6-hydroxymelatonin. Metabolomics analysis indicated that 6-hydroxymelatonin, 6-hydroxymelatonin glucuronide, and 6-hydroxymelatonin sulfate can be detected in urine after intraperitoneal injection of melatonin (Ma, Chen, Krausz, Idle, & Gonzalez, 2008; Ma et al., 2006) . A recent study revealed that melatonin is an inhibitor of CYP1A1, CYP1A2 and CYP1B1, and can decrease the incidence of tumorigenesis caused by benzo [a] anthracene (Chang, Chen, Yang, & Yeung, 2010) . Clinical studies revealed that melatonin can lower the intraocular pressure of glaucoma patients (Samples, Krause, & Lewy, 1988) and improve sleep disorders (Gringras, et al., 2012) . Numerous studies revealed that melatonin metabolism affects the nervous system and vision (Hardeland, Cardinali, Brown, & Pandi-Perumal, 2015; Lundmark, Pandi-Perumal, Srinivasan, & Cardinali, 2006) . Thus, CYP1B1 may affect the nervous system and vision via its regulation on melatonin metabolism.
Role of CYP1B1 in metabolic diseases
Inhibition of CYP1B1 prevents against obesity
Obesity, contributes to other metabolic diseases, particularly cardiovascular diseases, type-2 diabetes mellitus, non-alcoholic fatty liver and cancer. In 1998, it was first reported that the basal CYP1B1 protein expression was elevated by the differentiation of C3H10T1/2 cells to adipocytes (Zhang, Savas, Alexander, & Jefcoate, 1998) . Subsequent studies indicated that CYP1B1 expression can be substantially induced following the stimulation of C3H10T1/2 cells by an adipogenic hormonal mixture consisting of insulin, dexamethasone, and methylisobutylxanthine (Cho et al., 2005; Zheng et al., 2013) . The induction of PPARγ expression involved in adipogenesis was increased during the stimulation of C3H10T1/2 cells. Consistent with these observations, a review of 49 obesity-related genome-wide sequencing experiments covering 16,186 genes indicated that CYP1B1, interleukin 1 receptor, type I (IL1R1), and adiponectin, C1Q and collagen domain containing (ADIPOQ) were three of the highest scoring genes associated with obesity (English & Butte, 2007) , suggesting that CYP1B1 may have an important role in adipogenesis and obesity. In the mouse obesity model induced by HFD for 11 weeks, body weights, epididymis fat pad weights, and fat content in liver were significantly lower in Cyp1b1-null mice than in wild-type mice (Liu, Zhao, Feng, Colin, & Wang, 2012) . Microarray analysis indicated that CYP1B1 disruption altered the expression of 560 genes in the liver, including suppression of PPARγ, stearoyl CoA desaturase 1 (Scd1) and many genes stimulated by PPARα which are associated with energy homeostasis (Larsen et al., 2015) . Among these genes, 17 genes changes in Cyp1b1-null mice contributed to the attenuation of diet-induced diabetes. A recent study indicated that CYP1B1 deficiency can attenuate HFD-induced obesity and improved glucose tolerance (Liu et al., 2015) . The expressions of PPARγ signaling, CD36, fatty acid synthase (FAS), and SCD1 involved in fatty acid transport and synthesis were decreased in the liver, and the genes uncoupling protein 2 (Ucp2) and carnitine palmitoyltransferase 1a (Cpt1a), responsible for fatty acid oxidation, were increased. However, knock down of CYP1B1 in C3H10T1/2 cells did not abolish adipogenesis induced by adipogenic agents (Liu et al., 2015) , suggesting that the mechanism of CYP1B1 regulating obesity needs further examination.
Metabolomics profiling revealed changes in endogenous metabolites associated with obesity. Examples include plasma lysophosphatidylcholines and phosphatidylcholines in adult obese men and children with obesity (Pietilainen et al., 2007) . A metabolomics study found that lysophosphatidylcholine 18:0 (LPC 18:0) is a biomarker positively related to HFD-induced obesity in mice (Li et al., 2014) .
Consistent with the LPC 18:0 changes, the hepatic expression of phosphatecytidylyltransferase 1β (PCYT1β) involved in lysophosphatidylcholine synthesis showed a similar trend between lean and obese mice. The increased serum LPC 18:0 in wild-type mice could be significantly reduced in Cyp1b1-null mice with the lean phenotype. Compared to wild-type mice, CYP1B1-humanized mice showed a similar level of LPC 18:0 as wild-type mice, suggesting human CYP1B1 and mouse CYP1B1 showed the same response to HFD challenge. Further studies indicated that hepatic SCD1 expression also contributed to the changes of lysophosphatidycholines. SCD1 catalyzes saturated fatty acids from the diet to monounsaturated fatty acids, which is a critical control point in the development of obesity and insulin resistance (Flowers & Ntambi, 2008) . Taken together, these data demonstrate that CYP1B1 influences adipogenesis (Fig. 8) .
Inhibition of CYP1B1 minimizes hypertension
Hypertension is the leading cause of cardiovascular diseases. CYP1B1 is mainly expressed in extra-hepatic tissues, including the cardiovascular system (Korashy & El-Kadi, 2006) . In blood vessels, CYP1B1 is mostly expressed in vessel smooth muscle cells (VSMCs) and slightly expressed in endothelial cells (Conway et al., 2009 ). CYP1B1 mediates some important physiological processes in the blood vessel, notably the development and maintenance of hypertension. In angiotensin II (Ang II)-dependent hypertension, CYP1B1 is responsible for Ang II inducedvascular smooth muscle cell migration, proliferation and protein synthesis via the regulation of AA metabolism (Yaghini et al., 2010) . AA is metabolized by CYP1B1 to 12-and 20-hydroxyeicosatetraenoic acids, which generate reactive oxygen species (ROS) (Trevisi, Bova, Cargnelli, Ceolotto, & Luciani, 2002) . Inhibition of CYP1B1 by TMS can reduce ROS production and extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase activity, resulting in decreased hypertension (Yaghini et al., 2010) . A subsequent study found that the blood pressure increased by Ang II can be reduced in Cyp1b1-null mice compared to wild-type mice (Jennings et al., 2010) . Consistent with this study, the modulation of CYP1B1 by 2-methoxyestradiol can protect against Ang II-induced hypertension and cardiovascular changes in female mice (Jennings, George, et al., 2014) . 6β-Hydroxytestoterone produced by CYP1B1 can restore the increased systolic blood pressure and cardiac hypertrophy, and fibrosis induced by Ang II, whereas these pathological characteristics were minimized in Cyp1b1-null or castrated Cyp1b1-null mice (Pingili et al., 2015) . Similarly, CYP1B1 also mediates Ang II-independent hypertension by reducing ROS production and activity of ERK1/2 and p38 MAPK. TMS can normalize the blood pressure deoxycorticosterone acetate (DOCA)-salt-induced hypertension which elevates salt and water retention, and increases the levels of vasopressin, endothelin-1 and catecholamine (Sahan-Firat et al., 2010) . In a model of pulmonary arterial hypertension induced by dexfenfluramine, the expression of CYP1B1 was elevated in human pulmonary artery smooth muscle cells. Another study found that CYP1B1 was critical in the development of dexfenfluramine-induced pulmonary arterial hypertension, and this effect was related to the metabolism of estrogen (Dempsie et al., 2013) . Additionally, the aortic lesions, hypertension, and associated pathogenesis in Apoe −/− /Cyp1b1 +/+ mice on an atherogenic diet were dependent on CYP1B1-generated oxidative stress (Song et al., 2015) . Therefore, CYP1B1 could serve as a novel target for the developing drugs to treat different types of hypertension.
Inhibition of CYP1B1 contributes to the decrease of tumorigenesis
Cancer is a group of deadly diseases involving abnormal cell growth that has the potential to spread to other parts of the body. Numerous metabolomics studies have shown that the changes in endogenous metabolites are found in the fluids and tissues of cancer patients. By comparison of patients with liver cirrhosis, acute myeloid leukemia and healthy individuals, it was noted that the levels of glycodeoxycholate, deoxycholate 3-sulfate, and bilirubin were increased in hepatocellular carcinoma, whereas the levels of lysophosphocholines and free fatty acids such as lignoceric acid and nervonic acid were reduced in hepatocellular carcinoma (Patterson et al., 2011) . Another metabolomics analysis showed that the changes in asymmetric dimethylarginine, hexanoylglycine, and nicotinamide 1-oxide in urine were associated with the tumor size and number after squamous cell carcinoma (SCCVII) tumor cells grown as xenographs in mice (Li et al., 2013) . It was shown that CYP1B1 expression is enhanced in tumors, including prostate cancer (Tokizane et al., 2005) , breast cancer (Larsen et al., 1998) and colon cancer (Gibson et al., 2003) . Meta-analysis of clinical studies indicated that a CYP1B1 polymorphism was associated with a wide of variety of cancers, including lung cancer, breast cancer, and colon cancer (Li, Long, Qin, Li, & Zhou, 2015) . The detection of CYP1B1 expression might offer a novel method to diagnose renal cancer (McFadyen, Melvin, & Murray, 2004) . Some CYP1B1 inhibitors and monoclonal antibodies were developed for the treatment of certain cancers which show highly expressed CYP1B1 (McFadyen et al., 1999) . Thus, CYP1B1 may be a potential therapeutic target of cancer.
Metabolism of both endobiotics and xenobiotics by CYP1B1 might be assocated with increased carcinogenesis. As noted above, hydroxylation of estradiol catalyzed by CYP1B1 can generate DNA adducts. Many environmental procarcinogens can be activated by CYP1B1, including polycyclic aromatic hydrocarbons (PAH), aromatic amines, and nitropolycyclic hydrocarbons (Shimada et al., 1996) . In mouse models, ovarian cancer and skin cancer are the main cancers induced by DB[a,l]P, at approximately 71% and 47%, respectively. DB[a,l]P can be oxidized to (−)-trans-11,12-dihydrodiol by CYP1B1, and this metabolite is subsequently converted to (−)-anti-DB[a,l]PDE by CYP1B1 (Luch et al., 2000) . Reaction of (−)-anti-DB[a,l]PDE with 2′-deixyadenosine (Ado) generated DNA adducts, which was detected in mouse skin cancer after treated with DB[a,l]P (Fig. 9) (Buters et al., 2002) . The tumor incidence of DB[a,l]P was 100% in wild-type mice, however, the tumor incidence was decreased to 62% in Cyp1b1-null mice (Buters et al., 2002) . The tumorigenesis of other procarcinogens such as 7,12-dimethylbenz[a]anthracene (DMBA) and benzo[a]pyrene (B[a]P) were decreased in Cyp1b1-null mice (Buters et al., 2003; Uno et al., 2006) , demonstrating a role for CYP1B1 in procarcinogen-induced tumor formation. Thus, inhibition of CYP1B1 activity contributes to the decrease in the cancer risk induced by environmental procarcinogens.
Overexpression of human CYP1B1 was detected in a variety of tumors, but its level is lower or undetectable in normal tissues, indicating that CYP1B1 may be a target for cancer therapy. The anticancer agent flutamide, pacilitaxel, mitoxantrone and docetaxel are competitive inhibitors of CYP1B1, and tamoxifen is a noncompetitive inhibitor (Rochat et al., 2001 ). In the clinic, cancer patients frequently acquire resistance after long-term use of anticancer agents. One study showed that flutamide can be transformed into 2-hydroxylation flutamide by CYP1B1. However, 2-hydroxylation of flutamide did not show the anticancer effect (Rochat et al., 2001) . Interestingly, the anti-cancer drug flutamide was identified as an AHR agonist (Gao et al., 2016) , which may induce CYP1B1 expression, and the increased expression of CYP1B1 in certain tumors could decrease the tumor killing efficacy of flutamide. In another study, after long-term exposure to docetaxel, the cytotoxic effects of docetaxel was decreased in a hamster ovary cell line, however, the sensitivity to docetaxel cytotoxicity is recovered by co-incubation with the CYP1B1 inhibitor α-naphthoflavone (McFadyen et al., 2001 ). Therefore, co-administration of the anticancer agent and CYP1B1 inhibitors might decrease cancer resistance and enhance the outcome of anti-cancer therapy.
Glaucoma is associated with CYP1B1 mutation
Glaucoma is a leading cause of irreversible blindness. It is estimated that glaucoma will affect 80 million people by 2020 worldwide (Quigley & Broman, 2006) . Glaucoma is caused by continuous or intermittent elevation of IOP and anterior segment dysgenesis (ASD). Generally, glaucoma can be classified into three categories, primary open-angle glaucoma (POAG), primary congenital glaucoma (PCG), and primary angle closure glaucoma (PACG). Genetic analysis of glaucoma patients has identified CYP1B1 as a causative gene for PCG, and as a modifier gene in POAG. Study reported that 147 distinct mutations of CYP1B1 were verified in glaucoma patients, including missense mutations, nonsense mutations, duplication mutations, insertion mutations and deletion mutations (Li, Zhou, Du, Wei, & Chen, 2011) . The percentage of CYP1B1 mutations in patients is associated with their races. Generally, the incidence of African Americans is higher than Caucasians, and the incidence of Caucasians is higher than Asian (Bejjani et al., 1998; Colomb, Kaplan, & Garchon, 2004; Lim et al., 2013; Mashima et al., 2001; Melki, Colomb, Lefort, Brezin, & Garchon, 2004) . In 2003, Cyp1b1-null mice were first used to determine the role of CYP1B1 in PCG. It was noted that Cyp1b1-null mice exhibit ocular drainage structure abnormalities, which resemble the eye injury in human PCG patients (Libby et al., 2003) . Most recently, morphometric and semiquantitative analysis revealed that Cyp1b1-null mice present a decreased amount of trabecular meshwork (TM) collagen, higher TM endothelial cell, and collagen lesion scores (P b 0.005) compared to the age-matched controls; the collagen loss and lesion scores were progressively increased in older animals (Teixeira, Zhao, Dubielzig, Sorenson, & Sheibani, 2015) . Using the Cyp1b1-null mouse model, it was found that the tyrosinase gene (Tyr) was a modifier of the drainage structure phenotype, and the severe dysgenesis in eyes lacking both CYP1B1 and TYR can be alleviated by dihydroxyphenylalanine (L-dopa) (Libby et al., 2003) . Thus, selective upregulation of CYP1B1 expression in the eye could open new therapeutic avenues for the treatment of glaucoma.
It was proposed that several metabolic pathways regulated by CYP1B1 are relevant to the glaucoma. CYP1B1 is involved in the metabolism of vitamin A in which retinol is first oxidized to retinaldehyde, and then retinaldehyde is oxidized to retinoic acid. It is known that retinoid signaling regulates embryonic pattern formation during the development of eye, and vitamin A deficiency causes severe malformations of the developing eyes. Melatonin is metabolized primarily to 6-hydromelatonn by CYP1B1. Melatonin can be synthesized in the retina, lacrimal gland, lens, and ciliary body in the eye (Abe, Itoh, Miyata, Fig. 8 . Inhibition of CYP1B1 prevents obesity. CYP1B1 deletion diminishes the level of SCD1 expression in the liver, but SCD1 expression level can be normalized in CYP1B1-humanized mice. Studies showed that the deficiency of both CYP1B1 and SCD1 can enhance insulin sensitivity and prevent obesity from HFD challenge. In Cyp1b1-null mice, the expression of lipid synthesis genes are down-regulated, including pyruvate dehydrogenase kinase, isozyme 4 (PDK4), fatty acid synthase (FAS), malic enzyme 1 (ME1), and acetyl-coenzyme A carboxylase beta (ACACB), The target genes of PPARα involved in the fatty acid oxidation also are decreased, including CD36, ACOT1, ACOT2, CYP4A14, and aldo-keto reductase family 1, member C18 (AKR1C18) (Larsen et al., 2015) . These metabolic changes will cause decreased generation of phospholipid and tryglyceride. Study in Scd1-null mice have shown the similar changes that the expression of the genes related to lipid synthesis can be decreased such as sterol regulatory element-binding protein 1 (SREBP1), FAS, and, glycerol phosphate acyl-CoA transferase (GPAT). Conversely, the expressions of gene involved in fatty acid oxidation are increased, including CPT1, very long chain acyl-CoA dehydrogenase (VLCAD), and acyl-CoA oxidase (ACO) (Ntambi et al., 2002) . The reduced adipogenesis finally leads to the decrease of weight gain. Ishikawa, & Sumi, 1999; Mhatre, van Jaarsveld, & Reiter, 1988; Tosini & Menaker, 1998) , and melatonin was detected in aqueous humor and the ciradia rhythm of the plasma during the night cycle (Yu, Yee, Howes, & Reiter, 1990) . It was reported that the acute suppression of melatonin output to light was markedly reduced when chick pineal cells were depleted of vitamin A. Addition of retinaldehyde specifically restored the acute response, suggesting that a link between CYP1B1-mediated retinal and melatonin metabolism (Zatz, 1994) . However, the exact mechanism remains unclear. Melatonin modulates retinomotor movements, photoreceptors, dopamine synthesis and release, and IOP. 12-(R)-HETE formed from arachidonic acid by CYP1B1 is a potent inhibitor of Na + -K + -ATPase activity, which regulates corneal transparency and affects corneal susceptibility to pressure (Masferrer, Dunn, et al., 1990; Masferrer, Rios, et al., 1990) . Modulation of this ATPase activity further promotes the corneal clouding associated with glaucoma. Another study indicated that 12-(R)-HETE can lower IOP in rabbits (Masferrer, Dunn, et al., 1990; Masferrer, Rios, et al., 1990) . A clinical study found that levels of fasting serum glucose and uric acid were increased in glaucoma patients compared to the control population (Elisaf et al., 2001) . The incidences of diabetes mellitus, hyperlipidemia, diabetes, and hypertension in glaucoma patients were significantly higher than the control population (Chopra, Chander, & Jacob, 2012) . Lipidomics analysis revealed that a number of phospholipids were uniquely present in controls but absent in glaucomatous TM and vice versa (Aribindi, Guerra, Lee, & Bhattacharya, 2013) . These data indicated that a disorder in endogenous metabolism in the eye might be related to the development of glaucoma.
Inhibition of CYP1B1 improves renal dysfunction
CYP1B1 is expressed in both normal and neoplastic kidney, and oxidizes AA to generate EETs and HETEs (Choudhary et al., 2004) . It was reported that 19-and 20-HETE regulate the vasoconstrictor response of endothelin-1 (Oyekan, Balazy, & McGiff, 1997) and Ang II (Carroll et al., 1996) in kidney, causing a decrease in glomerular filtration rate. 20-HETE inhibits Na + transport in the proximal tubule by blunting Na + -K + -ATPase, conversely, 19-HETE accelerates Na + transport (Schwartzman, Abraham, et al., 1985; Schwartzman, Ferreri, et al., 1985) . EETs also regulate glomerular filtration by stimulating the Na + / H + exchanger as well as natriuretic actions of Ang II in the proximal tubule (Harris, Homma, Jacobson, & Capdevila, 1990) . Thus, the metabolites of AA produced by CYP1B1 may be harmful to renal functions. Consistent with these observations, the enhanced levels of 12-and 20-HETEs in mouse kidney by Ang II infusion cause renal dysfunction, including increased water consumption and urine output, decreased urine osmolality, increased urinary Na + and K + excretion, and proteinuria and albuminuria (Jennings, Anderson, et al., 2012) . The renal dysfunction and reactive oxygen species induced by Ang II can be diminished by TMS treatment and in Cyp1b1-null mice (Jennings, Anderson, et al., 2012) . The CYP1B1 deficiency also can minimize renal fibrosis, tubular damage, and inflammation after infusion with Ang II for 28 days. However, 50% of the 12-month old female Cyp1b1-null mice developed an unusual progressive glomerulonephritis while similar renal lesions were found in old male Cyp1b1-null mice later in life (Ward et al., 2004) . In another renal dysfunction model induced by DOCA, CYP1B1 deficiency resulted in decreased renal vascular resistance, renal infiltration of macrophages and T lymphocytes, and the production of reactive oxygen species (Jennings, Estes, et al., 2012) . The increased activities of extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, and cellular-Src were reduced in the kidney of Cyp1b1-null mice. Additionally, TMS improved the renal dysfunction and renal fibrosis in spontaneously hypertensive rats (SHR) (Jennings, Montanez, et al., 2014) . Taken together, inhibition of CYP1B1 may be of value for the protection against renal damage induced by chemical or genetic mutation.
The potency of CYP1B1 inhibitors as clinical therapeutic agents
The fact that CYP1B1 modulates the metabolism of hormones, fatty acids, vitamin A and melatonin, suggest that CYP1B1 influences the development of metabolic diseases (Fig. 10) . Thus, CYP1B1 modulators could be considered as therapeutic agents to protect against metabolic diseases. TMS is a selective and potent CYP1B1 inhibitor and its effects on several metabolic diseases have been determined, including tumorigenesis, hypertension, atherosclerosis, and adipogenesis. TMS could decrease blood pressure in several hypertension models induced by chemicals and gene mutation. The blood pressure from Ang II-and DOCA-induced hypertension was normalized by TMS via the decrease of ROS production and extracellular signal-regulated kinase activity (Sahan-Firat et al., 2010; Yaghini et al., 2010) . In ApoE −/− /Cyp1b1 +/+ mice on an atherogenic diet, TMS minimized the blood pressure, plasma lipid levels, and ROS (Song et al., 2015) . In spontaneously hypertensive rats, TMS reversed the increased blood pressure, reduced the plasma levels of nitrite/nitrate, pro-inflammatory cytokines, and diminished ROS production (Jennings, Montanez, et al., 2014) . More recently, one study indicated that TMS can suppressed the adipogenic differentiation of C3H10T1/2 cells by inhibiting PPARγ (Fan, Zhu, Huang, Li, & Wang, 2015) , suggesting that TMS treatment might protect against the obesity. Since CYP1B1 is overexpressed in tumor cells, it may be a potential therapeutic target for cancer treatment. However, its expression in many normal tissues, albeit at low levels suggest caution. However, the fact that Cyp1b1-null mice are normal, other than an increase in IOP suggest that inhibition of or CYP1B1 would not result in toxicities (Buters et al., 1999 ). An increasing number of CYP1B1 inhibitors have developed and patented (Cui et al., 2015; Kumar & Gupta, 2016) . In addition, ZYC300 is a CYP1B1-based vaccine which stimulates the immune system to elicit a cytotoxic T lymphocyte response against tumor cells expressing CYP1B1 (Maecker et al., 2003) . A phase I trial of ZYC300 was conducted in late stage cancer patients at Dana-Farber Cancer Institute at Boston, and the results indicated that the amount of vaccine dosed to patients was correlated with a decrease of cancer progression, and increased survival when an immune response was produced to CYP1B1 (McFadyen & Murray, 2005) . Another phase I open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing (NCT00381173) was completed at Dana-Farber Cancer Institute and M. D. Anderson Cancer Center (McFadyen & Murray, 2005) . A phase II clinical trial of ZYC300 is underway in recurrent glioblastoma multiforme patients (McFadyen & Murray, 2005) . These results suggested that a CYP1B1 inhibitor could be a promising therapeutic agent for metabolic diseases.
One potential application of CYP1B1 inhibitors is the treatment of anticancer drug resistance. An in vitro study showed that TMS inhibited the growth of tamoxifen-treated MCF-7 cells by 80% and fulvestranttreated MCF-7 cells by 70% (Park et al., 2007) . A subsequent in vivo study found that 8 weeks of treatment with TMS reduced tumor volume of breast cancer from tamoxifen-resistant MCF-7 cells xenograft by 53%. Additionally, TMS also can inhibit tubulin polymerization, microtubule formation, the activated focal adhesion kinase, and mammalian target of rapamycin, and stimulate c-jun-NH2-kinase and p38 mitogenactivated protein kinase activity, suggesting that TMS is a promising therapeutic agent for hormone-resistance breast cancer. A recent study revealed that the CYP1B1 was overexpressed in primary and metastatic loci of epithelial ovarian cancers. Exposure to α-naphthoflavone, a specific CYP1B1 inhibitor, can reduce paclitaxel resistance and enhance the sensitivity of ovary cells to paclitaxel in vitro and in xenograft model of nude mice (Zhu et al., 2015) . In renal cell cancer (RCC), the loss of miR-200c upregulated the expression of CYP1B1, which might be the underlying mechanism for the resistance of RCC cells to docetaxel (Chang et al., 2015) . Consistent with this study, a new water-soluble α-naphthoflavone derivative which shows highly selective inhibitory activity toward CYP1B1 (IC 50 = 0.043 nM) can eliminate the docetaxel-resistance caused by the enhanced CYP1B1expression in MCF-7/1B1 cells (Cui et al., 2015) . Taken together, these studies suggest that CYP1B1 inhibitors could overcome anticancer drug resistance.
Conclusion
CYP1B1 is a unique and important CYP. CYP1B1 carried out the metabolism of many xenobiotics and is involved in the metabolic activation of procarcinogens. The utilization of both CYP1B1 inhibitors and Cyp1b1-null mice has demonstrated that CYP1B1 modulates many endogenous metabolic pathways. The studies discussed in the current review suggest that CYP1B1 inhibitors may be effective in the treatment of hypertension, obesity, and atherosclerosis. However, to our knowledge, the clinical use of CYP1B1 inhibitors has not been reported. In contrast to other CYPs, CYP1B1 is expressed in many extra-hepatic tissues and a variety of tumor tissues. Studies indicate that CYP1B1 inhibitors can decrease the carcinogenesis of procarcinogens, and minimize the resistance of some anticancer drugs. Thus, specific CYP1B1 inhibitors may be considered as a potential therapeutic strategy for the treatment of metabolic diseases.
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